CA2528549A1 - Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer - Google Patents

Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer Download PDF

Info

Publication number
CA2528549A1
CA2528549A1 CA002528549A CA2528549A CA2528549A1 CA 2528549 A1 CA2528549 A1 CA 2528549A1 CA 002528549 A CA002528549 A CA 002528549A CA 2528549 A CA2528549 A CA 2528549A CA 2528549 A1 CA2528549 A1 CA 2528549A1
Authority
CA
Canada
Prior art keywords
epha4
antibody
cancer
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002528549A
Other languages
English (en)
French (fr)
Inventor
Kelly Carles-Kinch
Michael S. Kinch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2528549A1 publication Critical patent/CA2528549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002528549A 2003-06-06 2004-06-07 Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer Abandoned CA2528549A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47690903P 2003-06-06 2003-06-06
US60/476,909 2003-06-06
US50335603P 2003-09-16 2003-09-16
US60/503,356 2003-09-16
PCT/US2004/018279 WO2005048917A2 (en) 2003-06-06 2004-06-07 Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer

Publications (1)

Publication Number Publication Date
CA2528549A1 true CA2528549A1 (en) 2005-06-02

Family

ID=34622735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002528549A Abandoned CA2528549A1 (en) 2003-06-06 2004-06-07 Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer

Country Status (7)

Country Link
US (2) US7604799B2 (https=)
EP (1) EP1638514A4 (https=)
JP (1) JP2007522096A (https=)
KR (1) KR20060034231A (https=)
AU (1) AU2004291026A1 (https=)
CA (1) CA2528549A1 (https=)
WO (1) WO2005048917A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US9032097B2 (en) * 2001-04-26 2015-05-12 Nokia Corporation Data communication with remote network node
CA2518912A1 (en) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
WO2005048917A2 (en) * 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US20070128116A1 (en) * 2005-07-27 2007-06-07 Wang Zheng J Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs
US7807459B2 (en) * 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
CA2633718A1 (en) * 2005-12-21 2007-07-05 Medimmune, Llc Affinity optimized epha2 agonistic antibodies and methods of use thereof
US8003098B2 (en) 2006-02-28 2011-08-23 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-EphA4 antibodies
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
WO2010114921A1 (en) * 2009-04-02 2010-10-07 Burnham Institute For Medical Research Eph receptor ligands and methods of use
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012078703A2 (en) * 2010-12-08 2012-06-14 Fox Chase Cancer Center Inhibiting chromosome instability in ovarian cancer
WO2012118547A1 (en) * 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
EP2703814B1 (en) * 2011-04-25 2017-11-01 Eisai R&D Management Co., Ltd. Method for detecting neurological disease associated with cognitive dysfunction by measuring epha4 extracellular domain
MX375324B (es) 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
WO2016176562A1 (en) * 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Novel epha4 inhibitors targeting its ligand binding domain
PE20181051A1 (es) * 2015-09-08 2018-07-03 Eisai Randd Man Co Ltd Anticuerpo anti-epha4
CN108108589B (zh) * 2017-12-29 2020-06-12 郑州轻工业学院 基于网络指标差异分析的食管鳞癌标记物的识别方法
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
AU2021258282A1 (en) * 2020-04-23 2022-12-15 Research Institute At Nationwide Children's Hospital EphA4 targeting compounds and methods of use thereof
US11732007B2 (en) 2020-09-28 2023-08-22 The Regents Of The University Of California Therapeutic compounds and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US180823A (en) * 1876-08-08 Improvement in farm-gates
US28685A (en) * 1860-06-12 Peed-water apparatus for steam-boilers
US503356A (en) * 1893-08-15 Wire-netting machine
US476909A (en) * 1892-06-14 Rail-cleaning attachment for cars
US622711A (en) * 1899-04-11 render
US224374A (en) * 1880-02-10 Extension-ladder
US952560A (en) * 1909-06-28 1910-03-22 Gewerkschaft Der Stein Kohlenzeche Mont Cenis Process of obtaining ammonium sulfate from gases.
FI85768C (fi) * 1990-07-04 1992-05-25 Valtion Teknillinen Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare.
EP0517930B1 (en) * 1991-06-08 1995-05-24 Hewlett-Packard GmbH Method and apparatus for detecting the presence and/or concentration of biomolecules
GB9623820D0 (en) * 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
EP1080365A1 (de) * 1998-05-20 2001-03-07 Graffinity Pharmaceuticals Aktiengesellschaft Spr-sensor zur gleichzeitigen erfassung einer vielzahl von in fluider form vorliegenden proben
US6289286B1 (en) * 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
WO2001000678A1 (en) * 1999-06-30 2001-01-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
EP1358349A2 (en) 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
AU2001271502A1 (en) * 2000-06-26 2002-01-08 Gpc Biotech Ag Methods and compositions for isolating biologically active antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US20040028685A1 (en) 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
WO2005048917A2 (en) * 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES

Also Published As

Publication number Publication date
US20050013819A1 (en) 2005-01-20
WO2005048917A3 (en) 2009-03-26
JP2007522096A (ja) 2007-08-09
EP1638514A4 (en) 2009-11-18
WO2005048917A2 (en) 2005-06-02
US20100166657A1 (en) 2010-07-01
KR20060034231A (ko) 2006-04-21
EP1638514A2 (en) 2006-03-29
AU2004291026A1 (en) 2005-06-02
US7604799B2 (en) 2009-10-20

Similar Documents

Publication Publication Date Title
US7604799B2 (en) EphA4 Antibodies
AU2003243228B2 (en) EphA2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
JP4860477B2 (ja) ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
US20100143345A1 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2005016381A2 (en) Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
US20090220527A1 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
CN101227921A (zh) EphA4和EphA4调节剂用于诊断、治疗和预防癌症的用途
AU2012202569A1 (en) EPHA2 agonistic monoclonal antibodies and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20100607